Story perspectives
Breakthrough Therapy Shows Promise for Feline Cancer Treatment
8/30/2025
34 7
1 of 1
Story summary
- A phase 1 clinical trial evaluated a STAT3-targeted therapy for aggressive head and neck squamous cell carcinoma in cats.
- The therapy demonstrated a 35% response rate, with seven of 20 cats showing partial or stable disease.
- Median survival for treated cats was 161 days.
- Researchers plan to assess the drug's effectiveness in humans, emphasizing the role of companion animals in cancer research.
